07:00 EST Jazz Pharmaceuticals (JAZZ) to acquire Chimerix (CMRX) for $8.55 per share in cash
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Biotech Alert: Searches spiking for these stocks today
- Jazz Pharmaceuticals Reports Record Revenue Amid Growth Challenges
- Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
- Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Cost Management and Positive Market Developments
- Jazz Pharmaceuticals Faces DEI Challenges Amidst Executive Order and Growing Scrutiny